LexDanaLexDanabeta
Inventor

Robert M. Scarborough

Inventor
Half Moon Bay, CA, US

Overview

157→
Patents
1988–2018
Patent span
Chemistry
Primary field (CPC C)

Patents· 157 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%
C07DHeterocyclic compounds19%
C07KPeptides18%
C07CAcyclic or carbocyclic compounds6%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
C12NMicroorganisms or enzymes3%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests2%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture1%
C12YEnzymes1%
PatentTitleYear
9,932,364Antisense-based small RNA agents targeting the Gag open reading frame of HIV-1 RNA20189,221,758'Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor'20158,691,847'Benzamides and related inhibitors of factor Xa'20148,536,184'Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof'20138,524,721'Platelet ADP receptor inhibitors'20138,524,907'Methods of synthesizing pharmaceutical salts of a factor Xa inhibitor'20138,518,977'Benzamides and related inhibitors of factor XA'20138,377,974'Factor Xa inhibitors'20138,349,873'Factor XA inhibitors'20138,324,205'Quinazoline derivatives as kinase inhibitors'20128,268,857'Compositions and methods for inhibiting TGF-β'20128,153,670'Factor Xa inhibitors'2012RE043098'Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof'20128,067,428'Platelet ADP receptor inhibitors'20118,063,077'Factor Xa inhibitors'20118,063,036'Benzamides and related inhibitors of factor Xa'20118,058,284'[4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto'20118,022,071'Nitrogenous heterocyclic compounds'20117,943,640'Compositions and methods for inhibiting TGF-β'20117,834,143'Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor'20107,834,023'Substituted dihydroquinazolines as platelet ADP receptor inhibitors'20107,727,982'Benzamides and related inhibitors of factor Xa'20107,727,981'Benzamides and related inhibitors of factor Xa'20107,709,640'Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof'20107,696,352'Factor Xa inhibitors'20107,678,790'Platelet ADP receptor inhibitors'20107,678,913'Ureas as factor Xa inhibitors'20107,622,474'Platelet ADP receptor inhibitors'20097,612,089'Tetrahydroisoquinolines as factor Xa inhibitors'20097,560,461'Quinazoline derivatives as kinase inhibitors'20097,521,470'Factor Xa inhibitors'20097,417,030'Indazole peptidomimetics as thrombin receptor antagonists'20087,361,669'Compositions and method for inhibiting TGF-β'20087,358,257'Platelet ADP receptor inhibitors'20087,351,792'Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor'20087,342,013'Benzamides and related inhibitors of factor Xa'20087,329,655'Nitrogenous heterocyclic compounds'20087,314,939'Compositions and methods for inhibiting TGF-β'20087,314,874'Benzamides and related inhibitors of factor Xa'20087,312,235'Benzamide inhibitors of factor Xa'20077,294,635'Substituted isoquinolinones'20077,285,565'Benzamides and related inhibitors of factor Xa'20077,205,296'Substituted 2H-1,3-benzoxazin-4(3H)-ones'20077,189,733'Compositions and methods for inhibiting TGF-β'20077,179,790'Brain natriuretic peptide'20077,119,182'Recombinant thrombin receptor and related pharmaceuticals'20067,115,741'4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds'20067,109,332'2,4-dioxo-3-quinazolinylaryl sulfonylureas'20067,056,926'Platelet ADP receptor inhibitors'20067,049,297'Indazole peptidomimetics as thrombin receptor antagonists'20067,022,731'Platelet ADP receptor inhibitors'20066,982,266'Quinazoline derivatives as kinase inhibitors'20066,974,861'Pharmaceutical compositions and methods using natriuretic peptides'20056,960,580'Nitrogenous heterocyclic substituted quinoline compounds'20056,956,039'Nitrogenous heterocylic compounds'20056,951,937'Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof'20056,906,063'Platelet ADP receptor inhibitors'20056,903,227'Synthesis of 2-acyl substituted chromanes and intermediates thereof'20056,897,030'Immunoassays for human brain natriuretic peptide'20056,887,880'Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof'20056,855,833'Methods for producing amino substituted chromanes and intermediates thereof'20056,844,367'Benzamides and related inhibitors of factor Xa'20056,835,739'Benzamides and related inhibitors of factor Xa'20046,777,413'2-1H-quinolone and 2-1H-quinoxalone inhibitors of factor Xa'20046,720,317'Inhibitors of factor Xa'20046,693,109'Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation'20046,689,786'Platelet ADP receptor inhibitors'20046,686,368'Inhibitors of factor Xa'20046,673,817'Inhibitors of factor Xa'20046,667,306'Platelet ADP receptor inhibitors'20036,638,980'Inhibitors of factor Xa'20036,632,815'Inhibitors of factor Xa'20036,613,930'Methods for producing 3-cyano-and 4-cyano- benzoic acid derivative compounds'20036,586,396'Subcutaneous administration of natriuretic peptide'20036,552,079'Integrin antagonists'20036,548,517'Oxindole inhibitors of factor Xa'20036,545,054'Alkenyl and alkynyl compounds as inhibitors of factor Xa'20036,545,055'Inhibitors of factor Xa'20036,534,535'Inhibitors of factor Xa'20036,528,534'Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation'20036,525,076'Selective factor Xa inhibitors'20036,469,026'Isoquinolone inhibitors of factor Xa'20026,399,627'Inhibitors of factor Xa'20026,376,515'Benzamides and related inhibitors of factor Xa'20026,369,080'Selective factor Xa inhibitors'20026,369,063'Selective factor Xa inhibitors'20026,333,321'Selective factor Xa inhibitors'20016,297,026'Nucleic acids encoding the C140 receptor'20016,291,469'Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation'20016,262,047'Selective factor Xa inhibitors'20016,245,743'Inhibitors of factor Xa'20016,245,809'Integrin antagonists'20016,228,854'Selective factor Xa inhibitors'20016,218,382'Selective factor Xa inhibitors'20016,211,183'Selective factor Xa inhibitors'20016,211,154'Ketoheterocyclic inhibitors of factor Xa'20016,204,268'Selective factor Xa inhibitors'20016,197,748'Ketoheterocyclic inhibitors of factor Xa'20016,194,435'Lactams as selective factor Xa inhibitors'20016,133,256'Selective factor Xa inhibitors'20006,069,130'Ketoheterocyclic inhibitors of factor Xa'20006,063,794'Selective factor Xa inhibitors'20006,046,169'Inhibitors of factor XA'20006,043,212'Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor'20006,024,936'Antibody-based method of localizing activated thrombin receptors'20006,022,861'Ketoheterocyclic inhibitors of factor Xa'20005,968,902'Platelet aggregation inhibitors'19995,958,732'Platelet aggregation inhibitors'19995,948,761'Recombinant canine brain natriuretic peptide'19995,935,926'Platelet aggregation inhibitors'19995,919,765'Inhibitors of factor XA'19995,916,908'Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases'19995,874,400'Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor'19995,866,681'Thrombin receptor antagonists'19995,851,839'Platelet aggregation inhibitors'19985,843,897'Platelet aggregation inhibitors'19985,807,828'Platelet aggregation inhibitors'19985,807,825'Platelet aggregation inhibitors'19985,798,248'Recombinant mutant thrombin receptor and related pharmaceuticals'19985,795,868'Platelet aggregation inhibitors'19985,795,867'Platelet aggregation inhibitors'19985,786,333'Platelet aggregation inhibitors'19985,780,595'Platelet aggregation inhibitors'19985,770,564'Platelet aggregation inhibitors'19985,763,575'Agonist and antagonist peptides of the C140 receptor'19985,759,994'Recombinant thrombin receptor and related pharmaceuticals'19985,759,999'Platelet aggregation inhibitors'19985,756,451'Platelet aggregation inhibitors'19985,744,584'Antithrombosis agents'19985,736,339'Method utilizing purified GP IIb-IIIa to detect the presence of platelet aggregation inhibitors'19985,721,214'Inhibitors of factor Xa'19985,716,789'Method to determine ligands, agonist and antagonist of C140 receptor'19985,688,768'Recombinant thrombin receptor and related pharmaceuticals'19975,686,567'Platelet aggregation inhibitors'19975,686,566'Platelet aggregation inhibitors'19975,686,571'Platelet aggregation inhibitors'19975,686,569'Platelet aggregation inhibitors'19975,686,570'Platelet aggregation inhibitors'19975,686,568'Platelet aggregration inhibitors'19975,679,542'Antithrombosis agents'19975,674,710'Recombinant techniques for production of human brain natriuretic peptide'19975,629,174'Recombinant C140 receptor'19975,496,724'Genes encoding platelet aggregation inhibitors'19965,449,662'Atrial natriuretic peptide clearance inhibitors which resist degradation'19955,385,840'DNA encoding analogs of human alveolar surfactant protein SP-5'19955,344,783'Platelet aggregation inhibitors'19945,342,830'Antithrombosis agents'19945,318,899'Platelet aggregation inhibitors'19945,258,368'Atrial natriuretic/vasodilator peptide compounds'19935,212,286'Atrial Natriuretic/vasodilator peptide compounds'19935,169,761'DNA encoding and expression systems for alveolar surfactant proteins'19925,114,923'Recombinant techniques for production of novel natriuretic and vasodilator peptides'19925,104,853'Alveolar surfactant proteins having cys to ser mutations'19925,047,397'Linear analogs of atrial natriuretic peptides'19914,935,492'Cyclic analogs of atrial natriuretic peptides'19904,804,650'Analogs of atrial natriuretic peptides'19894,757,048'Synthetic analogs of atrial natriuretic peptides'1988

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1988–2007Based in Hayward, CA, US· patent location history
1992–2010Based in Belmont, CA, US· patent location history
1994–2002Patents assigned to COR THERAPEUTICS INC (60)· patent assignee history
2001–2015Based in Half Moon Bay, CA, US· patent location history
2002–2015Patents assigned to MILLENNIUM PHARM INC (50)· patent assignee history
2003–2013Patents assigned to PORTOLA PHARM INC (17)· patent assignee history
2006–2013Patents assigned to SCARBOROUGH ROBERT M (14)· patent assignee history
2011–2013Patents assigned to PANDEY ANJALI (6)· patent assignee history
2018Based in Montreal, CA· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
COR THERAPEUTICS INC601994–2002
MILLENNIUM PHARM INC502002–2015
PORTOLA PHARM INC172003–2013
SCARBOROUGH ROBERT Mself142006–2013
PANDEY ANJALI62011–2013
Locations
LocationPatentsSpan
Half Moon Bay, California, US732001–2015
Belmont, California, US691992–2010
Hayward, California, US141988–2007
Montreal, CA12018